Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107819 · ClinicalTrials.gov registry record
Metabolomics for Biomarker Discovery in Children With EoE
A clinical trial, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- 24
- Enrollment target
NCT03107819: Completed study, sponsored by The University of Texas Health Science Center, Houston.
NCT03107819 is a clinical trial that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03107819 has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The investigators are seeking to enroll 8 children ages 2-18 already undergoing upper endoscopy. For the purposes of research, a peripheral blood and clean catch urine specimen will be obtained to measure plasma and urine metabolomics. The data will be used to determine if there are any key differences in the metabolite profile of subjects found to have eosinophilic esophagitis (EoE) versus non-EoE subjects. Once these metabolites are identified, the investigators will seek to enroll many more subjects for a validation phase.
Primary Outcome
parts per million
Interventions
- DIAGNOSTIC_TEST Plasma and urine metabolomics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2018-03-31 |
What the finished NCT03107819 record still lists
NCT03107819 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Plasma and urine metabolomics is the first listed.
NCT03107819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03107819 about?
NCT03107819 is a clinical study titled "Metabolomics for Biomarker Discovery in Children With EoE". The investigators are seeking to enroll 8 children ages 2-18 already undergoing upper endoscopy. For the purposes of research, a peripheral blood and clean catch urine specimen will be obtained to measure plasma and urine metabolomics. The data will be used to determine if there are any key differen...
What is the current status of trial NCT03107819?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2017-03-29. Estimated completion is 2018-03-31.
What interventions are being tested in trial NCT03107819?
The interventions under investigation include: Plasma and urine metabolomics (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03107819?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI